Microcap Ledger Fulcrum Therapeutics, Inc. $FULC
Facts as of . Built from SEC filings and our own data. Small caps move fast; check the latest filings.
Snapshot
- Exchange
- Nasdaq Global Market
- Sector
- Pharmaceutical Preparations
- Headquarters
- Cambridge, MA
- Fiscal year end
- December 31
- Shares outstanding
- 76,297,257 [10-Q 2026-07-30]
What the company doesAI summary of filing
Fulcrum Therapeutics is a clinical-stage biopharmaceutical company developing small molecules to treat genetically defined rare diseases. Its lead product candidate, pociredir, is an oral small molecule in clinical development for sickle cell disease, designed to induce fetal hemoglobin; the company completed a Phase 1b trial and plans to initiate a registration-enabling trial in the second half of 2026. The company is pre-revenue and relies on its proprietary discovery approach to identify cellular drug targets that may modulate gene expression, with a secondary focus on exploring additional mechanisms for sickle cell disease and a preclinical program in prostate cancer. Fulcrum finances its operations through capital raises and has an accumulated deficit of $594.3 million as of December 31, 2025. [10-K 2026-02-24]
Financial health
| Period | Revenue | Net income | Operating cash flow | Cash | Filing |
|---|---|---|---|---|---|
| 6 months to Jun 2026 | — | −$45.07M | −$34.79M | $48.47M | [S-4 2026-09-02] |
| FY ended Dec 2025 | $0.00 | −$74.88M | −$60.06M | $197.53M | [S-4 2026-09-02] |
| FY ended Dec 2024 | $80.00M | −$9.72M | −$2.22M | $58.21M | [S-4 2026-09-02] |
- Quarterly cash burn
- −$17.39M
- Cash runway Estimate
- ~8.4 months
Capital structure and dilution
| Date | Shares outstanding | Filing |
|---|---|---|
| 2024-11-06 | 53,938,661 | [10-Q 2024-11-13] |
| 2025-02-18 | 53,979,306 | [10-K 2025-02-25] |
| 2025-04-24 | 53,979,306 | [10-Q 2025-05-01] |
| 2025-07-22 | 54,091,588 | [10-Q 2025-07-29] |
| 2025-10-22 | 54,118,438 | [10-Q 2025-10-29] |
| 2026-02-17 | 66,600,209 | [10-K 2026-02-24] |
| 2026-04-20 | 66,633,321 | [10-Q 2026-04-27] |
| 2026-07-23 | 76,297,257 | [10-Q 2026-07-30] |
- Shelf registration
- S-3 filed 2024-02-27; declared effective 2024-04-25 [S-3 2024-02-27]
Listing status
Current status: No Form 8-K Item 3.01 (listing notice) filings in the last 24 months, as of 2026-10-11.
Who owns it
| Date | Insider | Type | Shares | Price | Filing |
|---|---|---|---|---|---|
| 2026-07-17 | Tang Kevin | buy | 50,945 | $3.52 | [4 2026-07-20] |
| 2026-07-16 | Tang Kevin | buy | 116,671 | $3.56 | [4 2026-07-20] |
| 2026-07-15 | Tang Kevin | buy | 107,377 | $3.56 | [4 2026-07-15] |
| 2026-07-14 | Tang Kevin | buy | 53,651 | $3.56 | [4 2026-07-15] |
| 2026-07-14 | Tang Kevin | buy | 75,952 | $3.58 | [4 2026-07-15] |
| 2026-07-13 | Tang Kevin | buy | 12,966 | $3.54 | [4 2026-07-15] |
Catalysts and calendar
| Date | Type | Title |
|---|---|---|
| 2026-08-17 | 8-K | Material agreement entered; Unregistered sale of equity; Change in control |
| 2026-08-14 | 13G/A | Beneficial ownership report (5%+ holder) |
| 2026-08-14 | 13G | Beneficial ownership report (5%+ holder) |
| 2026-08-14 | 13G/A | Beneficial ownership report (5%+ holder) |
| 2026-08-14 | 13G/A | Beneficial ownership report (5%+ holder) |
| 2026-08-10 | 8-K | Director or officer change |
| 2026-08-03 | 13G | Beneficial ownership report (5%+ holder) |
| 2026-07-30 | 10-Q | Quarterly report |
| 2026-07-28 | 13G/A | Beneficial ownership report (5%+ holder) |
| 2026-07-17 | 13G | Beneficial ownership report (5%+ holder) |
| 2026-07-15 | 13G/A | Beneficial ownership report (5%+ holder) |
| 2026-06-25 | 13G | Beneficial ownership report (5%+ holder) |
Alerts for $FULC
Email me when Fulcrum Therapeutics, Inc. files an offering, gets a deficiency notice, or moves sharply.
Facts as of . Small caps move fast; check the latest filings.